Subject Diagnosis Age at study participation Age at diagnosis Duration of chemotherapy (months) Chemotherapy regimen Induction: prednisone, vincristine, doxorubicin, MTX, L-asparaginase CNS therapy: cranial radiation, vincristine, doxorubicin, 6-MP, IT MTX/ARA-C/hydrocortisone 1 ALL 39 35 14 Intensification therapy cycle 1–7: vincristine, dexamethasone, 6-MP, doxorubicin, asparaginase Intensification therapy cycle 8: vincristine, dexamethasone, 6-mercaptopurine, MTX Maintenance: vincristine, MTX, prednisone, 6-MP 2 AML 33 29 3
inductionHiDAC consolidation cycle 1 and 2 Induction: ATRA + idarubicin 3 APML 33 29 19 Consolidation cycle 1: ATRA, idarubicin Consolidation cycle 2: ATRA, mitoxantrone Maintenance: ATRA, 6-MP, MTX × 12 months Induction:
induction with ATRA 4 APML 27 25 7 Consolidation 1 and 2: arsenic trioxide Consolidation cycle 3 and 4: daunorubicin and ATRA Cycle 4: ATRA, MTX, 6MP × 12 months Prophase and induction: methylprednisolone, IT ARA-C, prednisone, vincristine, doxorubicin, MTX, PEG-asparaginase, IT MTX/ARA-C/hydrocortisone, IT MTX/hydrocortisone Consolidation IA: vincristine, doxorubicin, IT MTX/hydrocortisone, high-dose MTX, 6-MP Consolidation IB: cyclophosphamide, IT MTX/hydrocortisone, ARA-C, 6-MP 5 ALL 25 21 21 Consolidation IC: HiDAC, etoposide, dexamethasone, PEG-asparaginase PEG-asparaginase during consolidation IC and continued through CNS phase and consolidation II for 15 doses CNS therapy: vincristine, doxorubicin, 6-MP, dexamethasone, PEG-asparaginase, IT MTX/ARA-C/hydrocortisone, cranial radiation Consolidation II, Cycle 1–8: doxorubicin, dexamethasone, vincristine, 6-MP, PEG-asparaginase, MTX IT MTX/ ARA-C/hydrocortisone Continuation therapy, Cycle 1–20: dexamethasone, vincristine, 6-MP, MTX
